Truist analyst Richard Newitter lowered the firm’s price target on Zimmer Biomet (ZBH) to $113 from $118 and keeps a Hold rating on the shares.
Medical device maker Zimmer Biomet Holdings forecast full-year adjusted profit below Wall Street estimates on Thursday, as it ...
Zimmer Biomet shares at $105 reveal value at 13 times adjusted earnings, as the company continues to grow despite a GLP-1 ...
Zimmer Biomet agrees to acquire Paragon 28 for $1.1 billion, with a non-tradeable CVR up to $1 per share. Deal expected to ...
Zimmer Biomet (NYSE: ZBH) shares dipped slightly today on fourth-quarter results that came in just ahead of the consensus ...
Despite reporting better-than-expected Q4 2024 results, shares of Zimmer Biomet (NYSE:ZBH) fell in the morning hours Thursday after the orthopedic device maker set its 2025 outlook below consensus.
Analysts are pulling back from the Healthcare sector as 2 experts expressed today bearish sentiments on Zimmer Biomet Holdings (ZBH – Research ...
Zimmer Biomet made a major play in the foot and ankle treatment space today, announcing it will spend $1.2 billion to acquire ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results